Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7094781 | ACTELION | Sulfamides and their use as endothelin receptor antagonists |
Dec, 2025
(1 year, 7 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10946015 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
Sep, 2026
(2 years from now) | |
US9265762 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
May, 2027
(3 years from now) | |
US8367685 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
Oct, 2028
(4 years from now) | |
US8268847 | ACTELION | Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor |
Apr, 2029
(4 years from now) |
Opsumit is owned by Actelion.
Opsumit contains Macitentan.
Opsumit has a total of 5 drug patents out of which 0 drug patents have expired.
Opsumit was authorised for market use on 18 October, 2013.
Opsumit is available in tablet;oral dosage forms.
Opsumit can be used as method of treating pulmonary hypertension comprising administering macitentan in combination with a compound having phosphodiesterase-5 inhibitory properties, method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherein the polysorbate represents 0.1 to 1% of the weight of said pharmaceutical composition, method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherein the polysorbate represents 0.1 to 3% of the weight of said pharmaceutical composition.
Drug patent challenges can be filed against Opsumit from 18 October, 2017.
The generics of Opsumit are possible to be released after 18 April, 2029.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 18, 2018 |
Orphan Drug Exclusivity(ODE) | Oct 18, 2020 |
Orphan Drug Exclusivity(ODE-54) | Oct 18, 2020 |
Drugs and Companies using MACITENTAN ingredient
NCE-1 date: 18 October, 2017
Market Authorisation Date: 18 October, 2013
Treatment: Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherein the polysorbate represents 0.1 to 1% of the weight of ...
Dosage: TABLET;ORAL